News
Neoadjuvant dabrafenib and trametinib improves event-free survival in resectable melanoma
- Author:
- Andrew D. Bowser
The phase 2 trial was closed early due to the difference in event-free survival favoring the neoadjuvant approach.
News
Gene therapy moves from promise to reality
- Author:
- Andrew D. Bowser
Dr. Cynthia Dunbar, of the NIH, talks about the “critical mass of successes” in hematology and what is coming in the future.
News
Immune-modified RECIST can help identify survival benefit from cancer immunotherapy
- Author:
- Andrew D. Bowser
Analyses of early trials of atezolizumab for NSCLC and bladder cancer reveal aspects of immune-modified RECIST that seem to predict OS better than...
News
Thrombosis risk is elevated with myeloproliferative neoplasms
- Author:
- Andrew D. Bowser
Diagnosis appears to be the time with greatest risk.
News
POSH study: BRCA mutations did not influence survival in young onset breast cancer
- Author:
- Andrew D. Bowser
BRCA-positive and BRCA-negative women had similar overall survival at 2 years, 5 years, and 10 years after diagnosis.
News
S-1 regimen noninferior to other frontline mCRC options
- Author:
- Andrew D. Bowser
Frontline treatment with the oral fluoropyrimidine S-1 combined with irinotecan and bevacizumab was noninferior to other common regimens.
News
Rituximab may outperform some other first-line multiple sclerosis treatments
- Author:
- Andrew D. Bowser
Real-world effectiveness study in Sweden found rituximab had lowest discontinuation rate of all disease-modifying treatments studied.
News
BTK inhibitor zanubrutinib active in non-Hodgkin lymphomas
- Author:
- Andrew D. Bowser
ATLANTA – Response rates ranged from 31% to 88% depending on the lymphoma subtype.
News
Sequential chemotherapy and radiotherapy may be best in locally advanced NSCLC with negative margins
- Author:
- Andrew D. Bowser
For patients with R0 pN2 NSCLC, median overall survival was 58.8 months for sequential chemotherapy followed by radiation, versus 40.4 months for...
News
Rare neurological complication linked to Waldenstrom disease
- Author:
- Andrew D. Bowser
A 67-year-old man with Waldenstrom disease experienced bilateral facial nerve palsy.
News
Rituximab may be best choice for splenic MZL
- Author:
- Andrew D. Bowser
Rituximab monotherapy appears to outperform splenectomy based on retrospective data.
Video
VIDEO: Ibrutinib PFS is nearly 3 years in MCL patients who had one prior therapy
- Author:
- Andrew D. Bowser
ATLANTA – Dr. Simon Rule discusses the implications of the study and how ibrutinib stacks up against other therapies for MCL.
News
VTE rates in lenalidomide-treated NHL may warrant prophylaxis
- Author:
- Andrew D. Bowser
ATLANTA – Lenalidomide as single agent had twice the VTE rate as lenalidomide with a biologic.
News
Azacitidine maintenance improves PFS in older AML patients
- Author:
- Andrew D. Bowser
ATLANTA – A randomized, multicenter trial sheds light on care of older AML patients after chemotherapy.
News
CLL drug combinations induce MRD negativity
- Author:
- Andrew D. Bowser
ATLANTA – The potential of two- and three-drug combinations to induce MRD-negative responses in CLL patients was demonstrated in multiple studies...